{"id":"https://openalex.org/W1704878397","doi":"https://doi.org/10.3109/10428190009089437","title":"A Prospective Randomized Study of Alpha-2b Interferon plus Hydroxyurea or Cytarabine for Patients with Early Chronic Phase Chronic Myelogenous Leukemia: The International Oncology Study Group CML1 Study","display_name":"A Prospective Randomized Study of Alpha-2b Interferon plus Hydroxyurea or Cytarabine for Patients with Early Chronic Phase Chronic Myelogenous Leukemia: The International Oncology Study Group CML1 Study","publication_year":2000,"publication_date":"2000-01-01","ids":{"openalex":"https://openalex.org/W1704878397","doi":"https://doi.org/10.3109/10428190009089437","mag":"1704878397","pmid":"https://pubmed.ncbi.nlm.nih.gov/10752988"},"language":"en","primary_location":{"id":"doi:10.3109/10428190009089437","doi":"https://doi.org/10.3109/10428190009089437","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428190009089437","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Francis J. Giles","raw_affiliation_strings":["The International Oncology Study Group, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International Oncology Study Group, Houston, Texas, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103417990","display_name":"Jianqin Shan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianqin Shan","raw_affiliation_strings":["The International Oncology Study Group, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International Oncology Study Group, Houston, Texas, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shanshan Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shanshan Chen","raw_affiliation_strings":["Bejing Medical University, Beijing, PR China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bejing Medical University, Beijing, PR China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112411716","display_name":"Suresh Hariram Advani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800098698","display_name":"Tata Memorial Hospital","ror":"https://ror.org/010842375","country_code":"IN","type":"healthcare","lineage":["https://openalex.org/I2800098698"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Suresh H. Advani","raw_affiliation_strings":["Tata Memorial Hospital, Parel, Bombay, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tata Memorial Hospital, Parel, Bombay, India","institution_ids":["https://openalex.org/I2800098698"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042195226","display_name":"Iman Supandiman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086620","display_name":"Dr. Hasan Sadikin General Hospital","ror":"https://ror.org/003392690","country_code":"ID","type":"healthcare","lineage":["https://openalex.org/I4210086620"]}],"countries":["ID"],"is_corresponding":false,"raw_author_name":"Iman Supandiman","raw_affiliation_strings":["Hasan Sadikin Hospital, Bandung, Indonesia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hasan Sadikin Hospital, Bandung, Indonesia","institution_ids":["https://openalex.org/I4210086620"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022249692","display_name":"Zeba Aziz","orcid":"https://orcid.org/0000-0001-5032-4503","observed_orcids":["https://orcid.org/0000-0001-5032-4503"]},"institutions":[{"id":"https://openalex.org/I205173300","display_name":"Allama Iqbal Medical College","ror":"https://ror.org/04vhsg885","country_code":"PK","type":"education","lineage":["https://openalex.org/I205173300"]}],"countries":["PK"],"is_corresponding":false,"raw_author_name":"Zeba Aziz","raw_affiliation_strings":["Allama Iqbal Medical College, Lahore, Pakistan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allama Iqbal Medical College, Lahore, Pakistan","institution_ids":["https://openalex.org/I205173300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074081047","display_name":"Alendry P. Caviles","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alendry P. Caviles","raw_affiliation_strings":["Children's Medical Center, Banaue St, Quezon City, Philippines"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Children's Medical Center, Banaue St, Quezon City, Philippines","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038038115","display_name":"Goh Yeow Tee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2251586001","display_name":"Singapore General Hospital","ror":"https://ror.org/036j6sg82","country_code":"SG","type":"healthcare","lineage":["https://openalex.org/I2251586001"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Goh Yeow Tee","raw_affiliation_strings":["Singapore General Hospital, Outram RdSingapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Singapore General Hospital, Outram RdSingapore","institution_ids":["https://openalex.org/I2251586001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077530623","display_name":"Martin Robert Chasen","orcid":"https://orcid.org/0000-0002-0406-9692","observed_orcids":["https://orcid.org/0000-0002-0406-9692"]},"institutions":[{"id":"https://openalex.org/I4405267691","display_name":"Saskatoon Cancer Centre","ror":"https://ror.org/03x513f48","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405267691"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Martin R. Chasen","raw_affiliation_strings":["Sandton Oncology Centre, Sandton, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandton Oncology Centre, Sandton, South Africa","institution_ids":["https://openalex.org/I4405267691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038125366","display_name":"Zahira Fahed","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zahira Fahed","raw_affiliation_strings":["Teshreen Military Hospital, Damascus, Syria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Teshreen Military Hospital, Damascus, Syria","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111818811","display_name":"Tsu-Yi Chao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1293718874","display_name":"Tri-Service General Hospital","ror":"https://ror.org/007h4qe29","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I1293718874"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Tsu-Yi Chao","raw_affiliation_strings":["Tri-Service General Hospital, Ding-Chow Rd, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tri-Service General Hospital, Ding-Chow Rd, Taipei, Taiwan","institution_ids":["https://openalex.org/I1293718874"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006810034","display_name":"Ismet Aydogdu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20126385","display_name":"Inonu University","ror":"https://ror.org/04asck240","country_code":"TR","type":"education","lineage":["https://openalex.org/I20126385"]}],"countries":["TR"],"is_corresponding":false,"raw_author_name":"Ismet Aydogdu","raw_affiliation_strings":["Inonu University, Malatya, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inonu University, Malatya, Turkey","institution_ids":["https://openalex.org/I20126385"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057140261","display_name":"Anne M. Lynott","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne M. Lynott","raw_affiliation_strings":["The International Oncology Study Group, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International Oncology Study Group, Houston, Texas, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5061285204"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.9052,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.71792035,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"37","issue":"3-4","first_page":"367","last_page":"377"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9359999895095825},{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.7770000100135803},{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.9599999785423279},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":1.0},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8370000123977661},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.718999981880188},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.875},{"id":"https://openalex.org/keywords/complete-hematologic-response","display_name":"complete hematologic response","score":0.7870000004768372}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8333001136779785},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.8309258222579956},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7064226865768433},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.6088477373123169},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.5152457356452942},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.493161141872406},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.46845054626464844},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4629642963409424},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4472193419933319},{"id":"https://openalex.org/C2779316324","wikidata":"https://www.wikidata.org/wiki/Q212272","display_name":"Hydroxycarbamide","level":3,"score":0.42706558108329773},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4164605438709259},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4012402594089508},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.36555445194244385},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23927471041679382},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.18167400360107422}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015466","descriptor_name":"Leukemia, Myeloid, Chronic-Phase","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015466","descriptor_name":"Leukemia, Myeloid, Chronic-Phase","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3109/10428190009089437","doi":"https://doi.org/10.3109/10428190009089437","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428190009089437","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},{"id":"pmid:10752988","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10752988","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & lymphoma","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W236820854","https://openalex.org/W642647645","https://openalex.org/W1901923962","https://openalex.org/W1981370967","https://openalex.org/W1984811023","https://openalex.org/W1987894899","https://openalex.org/W1989627056","https://openalex.org/W2008407529","https://openalex.org/W2010012100","https://openalex.org/W2015960969","https://openalex.org/W2026030564","https://openalex.org/W2026875692","https://openalex.org/W2032842397","https://openalex.org/W2040151652","https://openalex.org/W2041147795","https://openalex.org/W2058190985","https://openalex.org/W2089697181","https://openalex.org/W2091163331","https://openalex.org/W2092178926","https://openalex.org/W2093184367","https://openalex.org/W2122797075","https://openalex.org/W2129508862","https://openalex.org/W2137690891","https://openalex.org/W2145890687","https://openalex.org/W2159794614","https://openalex.org/W2163892045","https://openalex.org/W2279312736","https://openalex.org/W2337277825","https://openalex.org/W2342966738","https://openalex.org/W2394660193","https://openalex.org/W2395764214","https://openalex.org/W2398326766","https://openalex.org/W2405297260","https://openalex.org/W2409184464","https://openalex.org/W2412652566","https://openalex.org/W2414032300","https://openalex.org/W2417281040","https://openalex.org/W2438648923","https://openalex.org/W4247887669"],"related_works":["https://openalex.org/W2045180507","https://openalex.org/W2394660193","https://openalex.org/W4237472716","https://openalex.org/W2022754087","https://openalex.org/W6979109055","https://openalex.org/W2127774770","https://openalex.org/W2156553441","https://openalex.org/W2337277825","https://openalex.org/W2089722023","https://openalex.org/W2134824524"],"abstract_inverted_index":{"A":[0],"prospective":[1,55],"randomized":[2,56,86],"international":[3],"study":[4,57,67],"of":[5,28,41],"143":[6],"patients":[7,42],"showed":[8],"no":[9,183],"apparent":[10,184],"early":[11,81,185],"survival":[12,73,146,157,186],"advantage":[13,187],"conferred":[14,188],"by":[15,189],"combining":[16,190],"cytarabine,":[17,191],"rather":[18,192],"than":[19,193],"hydroxyurea,":[20,194],"with":[21,43,61,80,195],"INF":[22,59,89,196],"as":[23,104,132,163,197],"first-line":[24,36,198],"CML":[25,84,199],"therapy.":[26,200],"Combinations":[27],"alpha-interferon":[29],"(INF)":[30],"and":[31,112,120,122,128],"chemotherapeutic":[32],"agents":[33],"are":[34],"currently":[35],"therapy":[37],"for":[38],"the":[39,72,144,171],"majority":[40],"chronic":[44,82],"myeloid":[45],"leukemia":[46],"(CML).":[47],"The":[48,65],"International":[49],"Oncology":[50],"Study":[51],"Group":[52],"conducted":[53],"a":[54,108,115,123],"comparing":[58],"combined":[60],"hydroxyurea":[62,101],"or":[63,102,136],"cytarabine.":[64],"primary":[66],"aim":[68],"was":[69,148,158],"to":[70,87,106,113,165],"compare":[71],"durations":[74],"in":[75,150,170],"these":[76],"patient":[77],"cohorts.":[78],"Patients":[79],"phase":[83,138],"were":[85],"receive":[88],"5":[90],"million":[91],"units":[92],"(Mu)":[93],"given":[94],"five":[95],"times":[96],"per":[97],"week":[98],"subcutaneously":[99],"plus":[100],"cytarabine":[103],"required":[105],"achieve":[107],"complete":[109],"hematologic":[110],"response":[111],"maintain":[114],"WBC":[116],"count":[117,125],"between":[118,126],"2x10(9)/L":[119],"10x10(9)/L":[121],"platelet":[124],"75x10(9)/L":[127],"100x10(9)/L.":[129],"Therapy":[130],"continued":[131],"tolerated":[133],"unless":[134],"progressive":[135],"blast":[137],"disease":[139],"occurred.":[140],"At":[141],"36":[142],"months,":[143],"actuarial":[145],"rate":[147],"equivalent":[149],"both":[151],"groups:":[152],"HI":[153],"group":[154,173],"(79":[155],"patients)":[156],"85%":[159],"(95%":[160,167],"CI,":[161,168],"68-100%),":[162],"compared":[164],"95%":[166],"79-100%)":[169],"CI":[172],"(64":[174],"patients).":[175],"In":[176],"conclusion":[177],"if":[178],"seems":[179],"that":[180],"there":[181],"is":[182]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}